Sequence information
DRAVP ID DRAVPc034
Name Leronlimab(PRO 140)
Sequence Not available
Molecular Formula Not Available
Condition/Disease HIV infection, COVID-19
Group Phase Ⅲ clinical trial
Type Antibody
Description Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.4 It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.
Active sequence/Structure
External Links
DrugBank Accession Number DB05941
Pubchem ID 135308456
CHEMBL ID CHEMBL2109343
UNII Y1J4NP8FF0
CAS 674782-26-4
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04901689 | Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation | COVID-19 Pneumonia / Coronavirus Disease 2019 (COVID‑19) Treatment | Suspended (Pending DSMB evaluation) | Phase 3 | Hospital Israelita Albert Einstein |
| NCT04901676 | Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia | COVID-19 Pneumonia / Coronavirus Disease 2019 (COVID‑19) Treatment | Suspended (Pending DSMB evaluation) | Phase 3 | Hospital Israelita Albert Einstein |
| NCT04343651 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 2 | CytoDyn, Inc. |
| NCT04678830 | COVID-19 Long-Haulers Study | Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 2 | CytoDyn, Inc. |
| NCT02175680 | Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 2 | CytoDyn, Inc. |
| NCT00613379 | PRO 140 by IV Administration in Adults With HIV-1 Infection | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 2 | CytoDyn, Inc. |
| NCT02175680 | Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection | Human Immunodeficiency Virus (HIV) Infections Treatment | Completed | Phase 2 | CytoDyn, Inc. |
